Article
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
The Journal of molecular diagnostics : JMD - 1 Jan 2009
Jones Dan, Kamel-Reid Suzanne, Bahler David, Dong Henry, Elenitoba-Johnson Kojo, Press Richard, Quigley Neil, Rothberg Paul, Sabath Dan, Viswanatha David, Weck Karen, Zehnder James
Abstract excerpt
The BCR-ABL tyrosine kinase produced by the t(9;22)(q34;q11) translocation, also known as the Philadelphia chromosome, is the initiating event in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Targeting of BCR-ABL with tyrosine kinase inhibitors (TKIs) has resulted in rapid clinical responses in the vast majority of patients with CML and Philadelphia chromosome+ ALL. However, long-term...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.